BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29469964)

  • 1. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.
    Wagner JB; Abdel-Rahman S; Van Haandel L; Gaedigk A; Gaedigk R; Raghuveer G; Kauffman R; Leeder JS
    J Clin Pharmacol; 2018 Jun; 58(6):823-833. PubMed ID: 29469964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
    Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.
    Wagner JB; Abdel-Rahman S; Gaedigk A; Gaedigk R; Raghuveer G; Staggs VS; Van Haandel L; Leeder JS
    Clin Transl Sci; 2020 May; 13(3):628-637. PubMed ID: 31981411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia.
    Wagner JB; Abdel-Rahman S; Gaedigk R; Gaedigk A; Raghuveer G; Staggs VS; Kauffman R; Van Haandel L; Leeder JS
    Clin Pharmacol Ther; 2019 Jun; 105(6):1501-1512. PubMed ID: 30549267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
    Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
    Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.
    Wu X; Gong C; Weinstock J; Cheng J; Hu S; Venners SA; Hsu YH; Wu S; Zha X; Jiang S; Li Y; Pan F; Xu X
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):240S-247S. PubMed ID: 30336686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.
    Ogungbenro K; Wagner JB; Abdel-Rahman S; Leeder JS; Galetin A
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1227-1235. PubMed ID: 31172248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
    Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
    J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
    Poller B; Woessner R; Barve A; Tillmann HC; Vemula J; Nica A; Elbast W; Schiller H; End P; Camenisch G; Weiss M
    Pulm Pharmacol Ther; 2019 Aug; 57():101809. PubMed ID: 31195091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
    Sivkov A; Chernus N; Gorenkov R; Sivkov S; Sivkova S; Savina T
    Lipids Health Dis; 2021 Nov; 20(1):157. PubMed ID: 34749751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
    He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
    Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of
    Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
    Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
    Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.